Top News

Grünenthal, Mesoblast Partner on Innovative Cell Therapy for Chronic Low Back Pain

September 13, 2019

The companies will develop and commercialize a Phase III cell therapy candidate for treating chronic low back pain in a deal worth potentially $1 billion.

Vertex to Acquire Semma Therapeutics in $950-Million Deal

September 04, 2019

Vertex will use the acquisition to develop cell-based treatments for type 1 diabetes.

FDA Expands Scope of API Impurity Investigation

August 29, 2019

While downgrading the impact of nitrosamine impurities on patients, FDA vows to step up investigations for other drug types.

J&J Vows to Appeal $572-million Opioid Decision

August 27, 2019

A ruling in Oklahoma that Johnson & Johnson’s marketing efforts created a public nuisance may establish a precedent of other jurisdictions.

Bristol-Myers Squibb, Celgene to Divest Otezla to Amgen for $13.4 Billion

August 26, 2019

The transaction is part of Bristol-Myers Squibb’s proposed acquisition of Celgene.

Bayer to Sell Animal Health Biz to Elanco for $7.6 Billion

August 21, 2019

The divestiture is in line with Bayer’s strategy to focus on its life sciences business.

Pfizer Invests $500 Million into Its Gene Therapy Facility

August 21, 2019

Pfizer is investing $500 million for the construction of a state-of-the-art gene therapy manufacturing facility in Sanford, NC.

GSK US Pharma Head Steps Down

August 12, 2019

Jack Bailey, president, US Pharmaceuticals, GlaxoSmithKline, will step down from his position at the end of 2019 and will be succeeded by a Merck KGaA executive.

Bayer Acquires BlueRock Therapeutics, Boosts Cell Therapy Stake

August 09, 2019

The acquisition will boost Bayer’s cell-therapy development programs, with an initial focus on neurology, cardiology, and immunology.

FDA Approves Nine Generic Versions of Lyrica

July 22, 2019

The first generics of Lyrica have been approved by the FDA for neuropathic pain management and adjunctive therapy.